|Bid||73.36 x 900|
|Ask||73.52 x 900|
|Day's Range||73.10 - 74.15|
|52 Week Range||43.50 - 79.45|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||56.25|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.17|
Subscribe to Yahoo Finance Plus to view Fair Value for HAE
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced it has earned CE mark certification for its VASCADE® vascular closure and VASCADE MVP® venous vascular closure systems. The CE marking will allow Haemonetics to engage in the next steps of country-specific entrance of both products into the European Union (EU) and forms the basis for entry into other geographies that recogni
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.